Supernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.18, $0.05 better than the analyst estimate of $0.13. Revenue for the quarter came in at $50.4 million versus the consensus estimate of $49.67 million.

GUIDANCE:

Supernus Pharma sees FY2016 revenue of $200-210 million, versus the consensus of $207 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.